Last reviewed · How we verify
NCT03548597
Evaluation of the Diagnostic of Hepatic Fibrosis With the in Severe Obese Patients Candidates to Bariatric Surgery
trial testing Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery in Steatosis in 132 participants. Completed in 6 December 2016.
12 January 2015
Quick facts
| Lead sponsor | European Georges Pompidou Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 132 |
| Start date | 4 April 2012 |
| Primary completion | 12 January 2015 |
| Estimated completion | 6 December 2016 |
Drugs / interventions tested
- Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery
Conditions studied
- Steatosis — all drugs for Steatosis →
- Obesity — all drugs for Obesity →
- Fibrosis, Liver — all drugs for Fibrosis, Liver →
Sponsor
European Georges Pompidou Hospital
Who can join
Eligibility, any sex, with Steatosis or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: The XL probe of FibroScan was recently developed to realize liver stiffness measurements (LSM) in overweight patients. Severe obese patients have a high prevalence of liver injuries and could benefit of liver evaluation prior to bariatric surgery. Objectives: Assess the FibroScan applicability, reliability and diagnostic performances in severe obese patients' candidates for bariatric surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Diagnostic of hepatic fibrosis with the XL probe of the Fibroscan versus biopsies in patients candidates to bariatric surgery.
Barsamian C, Carette C, Sasso M, Poghosyan T, et al · · 2020 · cited 7× · PMID 32359748 · DOI 10.1016/j.clnesp.2020.02.010
Verify or expand the search:
- PubMed search for NCT03548597
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Steatosis
Currently open trials in the same condition.
- NCT06814600 — Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients · recruiting
Other European Georges Pompidou Hospital trials
Trials by the same sponsor.
- NCT07059715 — Mic Mac: Micro- and Macrocirculatory Assessment During Cardiac Surgery in Patients at Risk of Vasoplegic Syndrome: A Pro · recruiting
- NCT04407858 — Cardiovascular Complications of Carfilzomib · unknown
- NCT04407845 — Atrial Fibrillation in Patients Receiving Ibrutinib · unknown
- NCT07093320 — Saving Limbs After Cancer: Blood Vessel and Soft Tissue Reconstruction Following Sarcoma Surgery in the Legs · completed
- NCT04591509 — Predictability of Echographic Excursion of the Diaphragm for Intubation in COPD- Patients With Acute Respiratory Failure · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03548597 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by European Georges Pompidou Hospital
- Last refreshed: 7 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03548597.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing